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Abstract
Introduction
➢ Oral anticoagulants are commonly used long-term in patients with 
atrial fibrillation, a history of a mechanical heart valve, or a recent 
history of thromboembolic events.  
➢ It is estimated that 15-20% of chronically anticoagulated patients will 
undergo an elective or emergent surgery or procedure that will require 
anticoagulation interruption annually (Garwood et al., 2017).
➢ During this interruption period, “bridging” anticoagulant therapy is 
often utilized with unfractionated heparin or low-molecular weight 
heparin to ensure adequate anticoagulation is achieved and to reduce 
the risk of a thromboembolic event perioperatively (Ayoub et al., 
2016).
➢ Current debate whether thromboembolic events caused by 
perioperative anticoagulant interruption posts a larger risk for patients 
than intra/postoperative bleeding for those who initiate bridging 
therapy (Douketis et al., 2015). 
Research Question
Literature Review
Applicability to Clinical 
Practice
Discussion
➢ Siegal et al. (2012) found an increased risk in overall bleeding events 
was demonstrated in bridged patients compared to non-bridged 
patients (5.4 vs 3.6, 95% CI). Anticoagulant bridging therapy was 
associated with an overall increased risk of bleeding events in 13 
studies (odds ratio, 5.40; 95% CI, 3.00-9.74) and major bleeding 
events in five studies (odds ratio, 3.60; 95% CI, 1.52-8.50).
➢ According to the Ayoub et al. (2016) meta-analysis there was a 
significantly reduced risk in postoperative bleeding identified in the 
non-bridging group as compared to the bridging group (OR, 0.41; 
95% CI, 0.24-0.68; P=0.0006).
➢ Steinberg et al. (2015) found that the use of anticoagulant bridging 
therapy in patients with atrial fibrillation resulted in significantly 
higher overall bleeding risks (5.0% vs 1.3%; adjusted odds ratio, 3.84; 
P<0.0001). 
Individualized Risk Assessments
➢ Palaniswamy and Selvaraj (2011) found that patients with atrial 
fibrillation who undergo perioperative interruption of oral 
anticoagulation should be stratified based on their risk of 
thromboembolic event compared to bleeding. 
➢ Pengo et al. (2009) demonstrated that tailoring anticoagulant bridging 
therapy to a patient’s thromboembolic risk index was both an effective 
and safe strategy.
➢ Oprea, Noto, and Halaszynski (2016) performed a risk stratification 
review which  stressed the importance of basing treatment with 
anticoagulant bridging therapy on patient-specific conditions. 
Statement of the Problem
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➢ The long-term use of oral anticoagulants is common among high-
risk patient populations for the prevention of thromboembolic 
events such as stroke, pulmonary embolism, etc.  It is estimated that 
15-20% of chronically anticoagulated patients will undergo a 
surgery or procedure that will require anticoagulation interruption 
annually.  During this interruption period, “bridging” anticoagulant 
therapy is often utilized with unfractionated heparin or low-
molecular weight heparin to ensure adequate anticoagulation is 
achieved.  However, there has been an ongoing debate whether or 
not the benefits of perioperative anticoagulant bridging therapy 
outweigh its risks.  This literature review focuses on whether or not 
forgoing anticoagulant bridging therapy increases the risk of 
peri/postoperative thromboembolic events.  It also focuses on the 
whether or not initiating bridging therapy places patients at a higher 
risk for postoperative bleeding.  Finally, it focusses on the current 
recommendations and whether or not utilization of individualized 
risk assessment tools increases efficacy and safety in regards to 
determining appropriate bridging therapy.  The results of this 
literature review conclude that in low-risk patients there is sufficient 
evidence to support that non-bridging therapy is non-inferior to 
bridging therapy in the prevention of peri/postoperative 
thromboembolic events.  There is also evidence to support that 
anticoagulant bridging therapy may place low-risk patients at a 
significantly higher risk for peri/postoperative bleeding events.  
Finally, there appears to be sufficient evidence to support the use of 
individualized risk assessment tools to help guide clinicians in their 
decisions regarding anticoagulant bridging therapy.  
➢ Does forgoing perioperative anticoagulant bridging therapy in 
patients who are chronically anticoagulated place them at a higher 
risk for a postoperative thromboembolic event vs those patients 
who initiate bridging therapy?
➢ Does initiating perioperative anticoagulant bridging therapy in 
patients who are chronically anticoagulated place them at a higher 
risk for a major intra/postoperative bleeding event vs those 
patients who forgo bridging therapy? 
➢ Should patients undergoing perioperative anticoagulant 
interruption be assessed using individualized risk assessment tools 
vs standardized bridging protocols to determine the need for 
anticoagulant bridging therapy?
➢ There is currently a lack of updated evidence-based guidelines and 
recommendations in regards to indications for perioperative bridging 
therapy.
➢ The most recent antithrombotic guidelines come from the American 
College of Chest Physicians (ACCP) in 2012.
➢ Current guidelines are a low-level recommendation (Level 2-C)
➢ To date, there remains to be an anticoagulant bridging therapy that is 
universally accepted which tailors an individual’s thromboembolic 
risk factors (Pengo et al., 2009).
➢ There is a need for additional high-level studies, and evidence-based 
guidelines to help guide clinicians.
Anticoagulant Bridging Therapy: Thromboembolic Risks
➢ Douketis et al. (2016) found from their BRIDGE trial that the 
placebo group was non-inferior when compared to the dalterparin 
group in reducing thromboembolic risk.  Incidence rate of 0.4%  
(4 of 918) in placebo group compared to 0.3% (3 of 895) in the 
dalterparin group (risk difference, 0.1 percentage points, 95% 
confidence interval [CI], -0.6 to 0.8; P=0.01 for noninferiority).
➢ Bouillon et al. (2016) found no statistically significant difference 
in the occurrence of stroke/systemic embolism between the 
bridged and non-bridged groups at one-month of follow-up or 
later (HR 0.97, 95% CI 0.68 – 1.37, P=0.841 from 0-1 months 
follow-up, HR 0.98, 95% CI 0.67-1.43, P=0.899 from 2-3 months 
of follow-up). 
➢ Ayoub et al. (2016) found no statistically significant difference in 
all-cause mortality (OR, 1.29; 95% CI, 0.15-11.52; P=0.82), 
cerebral vascular accident (OR, 0.93; 95% CI, 0.34-2.51; P=0.88), 
or thromboembolic events (OR, 0.72; 95% CI, 0.72-2.80; P=0.64) 
between the heparin bridging group and the non-bridging group at 
30 days and up to 3 months.
➢ Ono et al. (2016) demonstrated similar incidences between the 
HBA and non-HBA groups for exogenous blood transfusion 
(23.3% vs 19.4%, P = 0.587) and thromboembolic events (4.1% vs 
3.2%, P =0.755).  The results demonstrate no significant rise in 
thromboembolic events with the non-HBA group as compared to 
the HBA group.
Anticoagulant Bridging Therapy: Bleeding Risks
➢ Douketis et al. (2016) found the occurrence of major bleeding 
events in the placebo group at 37 days post follow-up was 1.3% 
(12 of 918) compared to 3.2% (29 of 895) in the dalterparin group. 
These results indicate that the placebo group had superior 
outcomes in reducing bleeding risks as compared to the bridging 
group (relative risk, 0.41; 95% CI, 0.20 to 0.78; P=0.005 for 
superiority).
➢ Bouillon et al. (2016) as showed an increase in major bleeding 
events at one-month post-op follow-up in the bridging group as 
compared to the non-bridged group (0.47% vs 0.30%; P<0.001).  
However, in the 2-month and 3-month follow-ups there was no 
difference in bleeding events between the two groups (HR 0.93; 
95% CI, 0.70-1.23, P=0.593).
➢ Current data does not support the use of routine bridging in low-risk 
anticoagulated patients.
➢ Multiple studies showed no statistically significant difference in the 
rates of thromboembolic events between the bridged and non-bridged 
groups.
➢ According to Siegel et al. “The risk of thromboembolic events was not 
significantly different in bridged and non-bridged patients”.
➢ Forgoing bridging was associated with a risk of bleeding that was 
significantly lower than the risk associated with bridging
➢ Douketis et al. (2016) found that “bridging conferred a risk of major 
bleeding that was nearly triple the risk associated with no bridging”
➢ Thromboembolic risk should be weighed against the bleeding risk 
associated with the procedure  
➢ According to Siegel et al. (2012) patients receiving anticoagulant 
bridging perioperatively were at a 3-5-fold increase in overall and 
major bleeding events compared to patients who received no bridging 
therapy.
➢ Individualized risk assessment scores should be utilized when 
determining risk prior to administration of bridging therapy. 
➢ Forgoing bridging therapy may be non-inferior to bridging therapy in 
regards to thromboembolic prevention in low-risk patients. 
➢ Bridging therapy is associated with a significantly higher risk of 
bleeding events compared to non-bridging therapy. 
➢ Clinician's should utilize individualized risk assessment calculators 
(CHADS₂, HAS-BLED) to calculate a patients thromboembolic and 
bleeding risks to help guide clinicians in their decisions to use or 
forgo anticoagulant bridging therapy.  
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